A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients-Reference-Cited by-同舟云学术

A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients

Published:2021-04-29 Issue:6 Volume:100 Page:1497-1508
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Martínez Sánchez María P., ,Megías-Vericat Juan Eduardo^ORCID,Rodríguez-Veiga Rebeca,Vives Susana,Bergua Juan Miguel,Torrent Anna,Suárez-Varela Sara,Boluda Blanca,Martínez-López Joaquín,Cano-Ferri Isabel,Acuña-Cruz Evelyn,Torres-Miñana Laura,Martín-Herreros Beatriz,Serrano Alfons,Sempere Amparo,Barragán Eva,Sargas Claudia,Sanz Miguel,Martínez-Cuadrón David^ORCID,Montesinos Pau^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-021-04542-8.pdf

Reference26 articles.

1. Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, Montesinos P (2018) Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol 97(7):1115–1153

2. Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, Prieto-Fernandez J, García R, García-Huerta AJ, Barrios M, Benavente C, Pérez-Encinas M, Simiele A, Rodríguez-Macias G, Herrera-Puente P, Rodríguez-Veiga R, Martínez-Sánchez MP, Amador-Barciela ML, Riaza-Grau R, Sanz MA, the PETHEMA group (2016) A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol 174(5):700–710

3. Fung HY, Chook YM (2014) Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol 27:52–61

4. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT et al (2013) KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 161(1):117–127

5. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R (2012) Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 120(9):1765–1773

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond oncology: Selinexor’s journey into anti-inflammatory treatment and long-term management;Frontiers in Immunology;2024-05-10

2. XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway;Annals of Hematology;2024-03-23

3. Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells;Biomedicines;2023-12-07

4. Nuclear transport proteins: structure, function, and disease relevance;Signal Transduction and Targeted Therapy;2023-11-10

5. Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024;Acta Haematologica;2023-10-31